Anti-Human IgG Fc Specific - DyLight 550

Antibody Details

Product Details

Reactivity Species

Human

Host Species

Mouse

Immunogen

Purified Recombinant Human IgG Fc Specific (> 98%)

Product Concentration

0.2 mg/ml

Formulation

This DyLight® 550 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

Storage and Handling

This DyLight^® 550 conjugate is stable when stored at 2-8°C. Do not freeze.

Cross Reactivity

Cross-reactivity by ELISA against human myeloma proteins:
Human IgG1: 100%
Human IgG2: 100%
Human IgG3: 100%
Human IgG4: 100%
Human IgM: < 0.2%
Human IgA: < 0.1%
Human IgE: < 0.1%

There is no detectable binding to bovine, goat, horse sheep IgG.

NOTE: This Anti-Human IgG, Fc Fragment Specific (Clone HP6043) when conjugated to HRPO is validated for use in Enzyme Immunoassay for the detection of Human IgG, Fc Fragment Specific (Part No.: I-1200)

Country of Origin

USA

Shipping

Next Day 2-8°C

Excitation Laser

Yellow Laser (563 nm)

RRID

AB_2893845

Applications and Recommended Usage?
Quality Tested by Leinco

FC This antibody has been quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume.

Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity

Mouse Anti-Human IgG Fc Specific (Clone HP6043) recognizes an epitope on Human IgG Fc Specific. This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Antigen Distribution

Surface IgG is expressed on approximately 2% of normal human peripheral blood cells.

Antigen Details

Protein

IgG Fc Specific

PubMed

IgG Fc Specific

References & Citations

1. Reimer, C. B. et al. (1984) Hybridoma 3:263
2. Jefferies, R. et al. (1985) Immunol. Letters 10:223
3. Phillips, D. J. et al. (1987) Immunol. Letters 17:159

Technical Protocols